1. Background
The cancer is a major public health problem worldwide and approximately 10 million new cases of cancers were detected each year [1]. Cancer is a major cause of mortality in the world, mainly due to some late diagnosis and that many current treatments do not have the sufficient effectiveness [2]. Almost all the chemical anticancer agents are very toxic and have serious side effects on normal cells and therefore, the development of new anticancer drugs with high efficiencies and low toxicity is necessary [3, 4]. It is documented that over 60% of currently used anticancer agents are derived from natural sources, including plants, marine organisms and micro-organisms [5]. In recent years, the investigation about plant-derived materials with anti-cancer activities was considered because some of these materials have low toxicity on normal cells and greater effect on cancer cells [6]. Many studies showed that some plant-derived materials could increase the apoptosis rate of cancer cells and thus could decrease the mortality and morbidity of cancers [7-9]. Beta-ionone (Figure 1) is a carotenoids found in the Rosaceae family such as Rosa bourboniana and Rosa canina [10]. Previously, it is reported that beta-ionone possess a wide variety of physiological and biological activities, including antioxidant, antimutagenic and antifungal activities [11, 12]. Altogether, dietary studies revealed that this compound exhibits chemopreventive and antitumor activities [13, 14]. Recent studies have suggested that beta-ionone may protect free-radical-induced damage of DNA by a mechanism other than solely direct free-radical scavenging [15]. Moreover, several in vitro studies have investigated that beta-ionone cause inhibition of cellular transformation [11, 14].
![Chemical Structure of β-Ionone [(E)-4-(2, 6, 6-Trimethyl-1cyclohexen-1-yl)-3-Buten-2-One]](https://brieflands.com/journals/zjrms/articles/7364/figures/zjrms-18-6-7364-i001-preview-preview.webp "Chemical Structure of β-Ionone [(E)-4-(2, 6, 6-Trimethyl-1cyclohexen-1-yl)-3-Buten-2-One]")
Figure 1.
Chemical Structure of β-Ionone [(E)-4-(2, 6, 6-Trimethyl-1cyclohexen-1-yl)-3-Buten-2-One]
2. Objectives
To date, there is no report regarding the anti-proliferative and apoptosis effects of beta-ionone on K562 cell line. Hence, in this study, we investigated whether beta-ionone could inhibit cell growth and induce apoptosis in K562 cells.
3. Materials and Methods
3.1. Chemicals
In this experimental study, fetal bovine serum (FBS), penicillin, streptomycin, RPMI-1640 and trypan blue were purchased from Gibco BRL (Gaithersburg, MD, USA). Hoechst 33342 and beta-ionone were obtained from Sigma (St Louis, MO. USA). Annexin V-PI apoptosis detection kit was purchased from Roche (Applied Science, Germany).
3.2. Cell Culture
Human chronic myelogenic leukemia cell line K562 was purchased from Pasteur Institute of Iran (Tehran, Iran). These cells were maintained in RPMI 1640 medium supplemented with 10% heat inactivated FBS along with penicillin (100 units/mL) and streptomycin (100 µg/mL). The cells were grown in a humidified atmosphere of 5% CO2 at 37°C. Beta-ionone was dissolved in ethanol to obtain a 1 mM stock solution and its subsequent dilutions were made in Roswell Park memorial institute (RPMI) medium.
3.3. Cell Proliferation Assay
Cell proliferation was performed using MTT assay by described method [16]. In brief, 5 × 103 cells were incubated in 96 well plates in the presence of different concentration of beta-ionone (25, 50, 100, 200, 300 and 400 µm) for 24, 48, 72 and 96 hours in a final volume of 200 µL. At the end of the treatment, 20 µL of MTT (5 mg/mL in PBS) was added to each well and incubated for an additional 2 hours at 37°C. The purple-blue MTT formazan precipitated was dissolved in 200 µL of DMSO. Subsequently, the activity of the mitochondria that reflects cellular growth and viability was evaluated by measuring the optical density at 570 nm on microtiter plate reader. In this experiment, the imatinib as an effective drug against K562 cells was used as positive control.
3.4. Trypan Blue Exclusion Test
The cultured K562 cells were treated with different concentrations of beta-ionone (25, 50, 100 and 200 µm) for 24, 48, 72 and 96 hours. After incubation, the cultures were collected and stained with Trypan Blue at room temperature and the number of living and dead cells from the initial 100 cells both in the control and experimental groups was recorded.
Nuclear staining with Hoechst 33342: Cells were incubated with beta-ionone (25, 50, 100 and 200 µm) for 24 hours and subsequently were washed with PBS buffer, after fixation in freshly prepared ice-cold paraformaldehyde (0.1%) for 10 min, cells were stained with Hoechst 33342 (50 µm) for 1 min in the dark condition. Morphologic changes of cells were then observed under the fluorescent microscope and the percentage of apoptotic cells was determined after counting for at least 100 cells per treatment groups.
3.5. Flow Cytometric Analysis
K562 cells were treated with varying concentrations of beta-ionone (25, 50, 100 and 200 µm) for 24 hours. At the end of each treatment, K562 cells were collected and quantitative apoptotic death assay was performed by Annexin V/(propidium iodide) PI staining following manufacturer’s protocol, and subsequently the apoptotic cells were analyzed by flow cytometry. In this experiment, the imatinib as an effective drug against K562 cells was used as positive control.
3.6. Statistical Analysis
Each experiment was performed in triplicate. All data were represented as means ± standard deviation (SD) and analysis of variance (ANOVA) was performed for all comparisons. In this study, P value < 0.05 was accepted statistically significant.
4. Results
4.1. Proliferation Study
The effect of the beta-ionone on the growth of K562 leukemia cells was examined by MTT assay. The results showed that the cell proliferation was inhibited in the treated cells in a dose-dependent manner (Figure 2). The extent of inhibition increased significantly at 25 µm of beta-ionone which is continued to increase up to 200 µm of beta-ionone (P = 0.0008). As shown in Figure 2 treatment with 200 µm of beta-ionone had no significant effect compared to treatment with 300 and 400 µm of beta-ionone.
Figure 2.
Dose and Time Response of K562 Cell Growth to Beta-Ionone
4.2. Trypan Blue staining
The Trypan Blue staining showed that the K562 cells viabilities were inhibited in the treated cells in a dose-dependent manner (Figure 3). Under identical conditions, with the extension of the culture time in the presence of beta-ionone, cell viability had decreased significantly in compared to control group.
Figure 3.
The Percentage of Apoptotic K562 Cells After Treatment With Beta-Ionone With Different Concentrations for Different Time Periods (*P < 0.05)
4.3. Hoechst 33342 Staining Study
Further experiments were carried out to determine whether this anti-proliferative effect of beta-ionone on K562 cells viability was closely associated with apoptotic cell death. Cells treated with different concentrations of beta-ionone for 24 hours when stained with Hoechst 33342 and observed under a fluorescence microscope showed characteristic apoptotic features such as chromatin condensation and nuclear fragmentation. At least 100 cells were scored at random under a fluorescence microscope. The percentage of apoptotic cells was increased in a dose-dependent manner (Figure 4).
Figure 4.
Hoechst Staining of K562 Cells Treated With Different Concentrations of Beta-Ionone After 24 hours
4.4. Flow Cytometric Study
Beta-ionone induced apoptosis was confirmed by means of Annexin V/PI staining. As shown in the representative fluorescence-activated cell sorting (FACS) analysis scatter-grams (Figure 5), control cells showed a large viable cell population, while the treated cells with beta-ionone at 25, 50, 100 and 200 µm doses after 24 hours showed a shift from live cells to the apoptotic cells with a little change in necrotic cell population.
Figure 5.
Flow Cytometric Analysis of K562 Cells Treated With Different Concentrations of Beta-Ionone After 24 hours
5. Discussion
Chemotherapy has been used for cancer treatment approximately 70 years ago by suppressing the proliferation of cancer cells. However, despite the considerable progress made with the novel chemotherapy drugs, their toxicity to normal cells and drug resistance as well as adverse side effects have remained the major obstacles for the successful clinical use. Plant-derived material possess highly diverse and complex molecular structures compared to synthetic drugs and play an important role in human health and in the development of new anticancer drugs [2-5]. Among the various classes of plant-derived compounds, carotenoids have been shown to have beneficial effects against many disorders such as cancers [6, 17]. Carotenoids occur as hydrocarbon carotenes and oxygenated xanthophylls and were belonged to the group of plant terpenoids [9]. Previous studies have demonstrated a significant anti-cancer activity in some natural carotenoid such as lycopene [18], lovastatin [19] and butein [20]. Beta-ionone, an analogue of β-carotenoid, which is a constituent of vegetables and fruits, has been used in the experimental cancer treatment [10]. Experimental evidence for beta-ionone’s benefit was strongest for anti-oxidative, anti-inflammatory and antifungal [11, 14]. This carotenoid is a fragrance ingredient used in many fragrance compounds such as decorative cosmetics, fine fragrances, toilet soaps, shampoos and other toiletries, as well as in non-cosmetic products such as household detergents and cleaners [10]. Antitumor activities of beta-ionone have been demonstrated in breast cancer, melanoma and chemical-induced rat carcinogenesis [13]. In this investigation we have characterized the effect of beta-ionone on the proliferation of human leukemia cell line K562. We found that the beta-ionone significantly inhibited proliferation of K562 cells with a dose-dependent manner. Our data are in consistent with Liu et al. that showed β-ionone has an inhibitory effect on human gastric adenocarcinoma cells growth [21]. It would be compatible with the research by Zhu et al. who have studied the effect of β-ionone on in human osteosarcoma (U2os) cells and has showed that this plant-derived compound is able to inhibit cell proliferation [22], also compatible with the research by Jones et al. that examined the effect of β-ionone in human prostate tumor cells, and showed that β-ionone inhibited cell proliferation and activates apoptosis via the mitochondrial pathway [23]. In this case, similar observations have been reported in the previous studies with other natural plant products such as lycopene [24, 25], silymarin [26], curcumin [27], epigallocatechin-3-gallate [28], celastrol [29], tea polyphenol [30], berberine [31], gossypol [32], wogonin [33], Korean red ginseng extract [34] and Curcuma longa extract [35] in various cancer cell lines. Therefore, beta-ionone and other effective plant-derived materials could be considered as the promising strategy for developing the anticancer drugs. Our results demonstrated that beta-ionone might be a good candidate for inhibiting proliferation activity in leukemia. This is the first report regarding growth inhibition of K562 cells by beta-ionone but additional studies need to establish the efficacy of beta-ionone in leukemia cells from patients and animal models of leukemia, which might be useful in supporting a rationale for clinical trial in leukemia patients.
